Trial
NCT04051801
Multiple Ascending Dose Putative Cognitive Enhancer VU319
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Vanderbilt University Medical Center
Collaborators
—
Condition
Cognitive Impairment
Intervention
Dose Escalation of VU319
Why stopped
Further development has been outlicensed to Acadia Pharmaceuticals
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-05-28